Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.

Autor: Pasqualotto E; Federal University of Santa Catarina, Florianopolis, Brazil., Figueiredo Watanabe JM; State University of Piauí, Teresina, Brazil., Gewehr DM; Denton Cooley Institute of Research, Science and Technology, Curitiba, Paraná, Brazil.; Curitiba Heart Institute, Curitiba, Paraná, Brazil., da Silva Maintinguer R; Federal University of Santa Catarina, Florianopolis, Brazil., van de Sande-Lee S; Federal University of Santa Catarina, Florianopolis, Brazil., de Araujo GN; Institute of Cardiology of Santa Catarina, São José, Brazil.; Imperial Charity Hospital, Florianopolis, Brazil., Leal FS; Institute of Cardiology of Santa Catarina, São José, Brazil.; Imperial Charity Hospital, Florianopolis, Brazil., Pinheiro CEA; Federal University of Santa Catarina, Florianopolis, Brazil.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Jul; Vol. 25 (7), pp. 1794-1802. Date of Electronic Publication: 2023 Apr 03.
DOI: 10.1111/dom.15051
Abstrakt: Aim: To assess the efficacy of bexagliflozin in reducing glycated haemoglobin (HbA1c) and the occurrence of side effects in patients with type 2 diabetes (T2DM).
Methods: We searched the PubMed, Embase, Cochrane and ClinicalTrials.gov databases for placebo-controlled, randomized clinical trials published up until 15 February 2023. The primary outcome was change in HbA1c. We computed weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs).
Results: A total of six studies and 3111 patients were included, of whom 1951 were prescribed bexagliflozin. Compared with placebo, bexagliflozin significantly reduced HbA1c levels (WMD -0.53%; 95% CI -0.75, -0.31), fasting plasma glucose levels (WMD -1.45 mmol/L; 95% CI -2.32, -0.57), systolic blood pressure (WMD -4.66 mmHg; 95% CI -6.41, -2.92), diastolic blood pressure (WMD -2.12 mmHg; 95% CI -3.94, -0.30), body weight overall (WMD -1.61 kg; 95% CI -2.14, -1.07), and body weight in patients with a body mass index >25 kg/m 2 (WMD -2.05 kg; 95% CI -2.78, -1.31). The proportion of patients who achieved HbA1c < 7% was higher in patients who received bexagliflozin as compared with placebo (OR 1.94; 95% CI 1.36-2.78). There were no significant differences between groups regarding side effects such as hypoglycaemia, genital mycotic infection, urinary tract infection, diarrhoea, headache, nausea, polyuria, diabetic ketoacidosis, or all-cause mortality.
Conclusions: In this meta-analysis, the use of bexagliflozin was associated with improved clinical and laboratory measures in patients with T2DM compared with placebo, with a similar profile of side effects. These findings support the efficacy of bexagliflozin in the treatment of T2DM.
(© 2023 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: